NBIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neurocrine Biosciences Inc (NBIX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows strong financial growth and positive analyst sentiment, the technical indicators suggest a bearish trend, and there are no immediate positive trading signals or catalysts to justify an entry point right now.
The MACD is slightly positive but contracting, RSI is neutral at 34.847, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 130.706, with the nearest support at 127.669 and resistance at 133.743. The pre-market price is 126.78, down 0.78%, indicating bearish momentum.
Strong financial performance in Q4 2025 with revenue up 28.33% YoY, net income up 49.08% YoY, and EPS up 48.00% YoY. Analysts maintain positive ratings, with JPMorgan, Wolfe Research, and others highlighting strong growth potential for Ingrezza and Crenessity.
Bearish technical indicators and lack of significant trading trends from hedge funds or insiders. The stock has a 50% chance of declining by -1.46% in the next day and -7.9% in the next month based on historical patterns.
In Q4 2025, Neurocrine reported strong growth with revenue at $805.5M (+28.33% YoY), net income at $153.7M (+49.08% YoY), and EPS at 1.48 (+48.00% YoY). However, gross margin slightly declined to 97.82% (-0.71% YoY).
Analysts are generally positive on NBIX, with multiple firms maintaining Buy or Outperform ratings. Price targets range from $140 to $192, with JPMorgan and others highlighting strong growth potential for Ingrezza and Crenessity. However, some firms have slightly lowered price targets following Q4 earnings.
